The Minister of Health, Mónica García, visited today the new HIPRA Campus in Aiguaviva (Girona), the company’s biotechnological innovation center that is becoming one of Europe’s leading hubs for research, development, and production of vaccines and biotechnological products for global public health. The visit included a tour of the facilities, covering an area of 114,000 m², which house production buildings as well as corporate and research and development areas. The Minister also learned about HIPRA’s progress in public health and its contribution to strengthening Europe’s health autonomy and preparedness for future pandemics.

HIPRA’s COVID-19 vaccine available this campaign

During the visit, the Minister received first-hand information about the latest updates on HIPRA’s COVID-19 vaccine adapted to the LP.8.1 variant, which will be available in Spain during the 2025–2026 vaccination campaign.

“Soon we will have the vaccine available in health centers. It is a source of pride for our country, for innovation, and for Europe and Spain’s strategic autonomy to have an industry capable of developing the entire value chain—from research to production and commercialization,” the Minister announced.

Produced entirely in Spain, the HIPRA COVID-19 vaccine represents a decisive step toward European health autonomy, offering an effective, safe, and accessible alternative against COVID-19. The European Commission has signed a framework agreement with HIPRA for the acquisition of up to 4 million doses over two years, ensuring that Europe maintains its own production capacity for future vaccination campaigns.

HIPRA, a key partner for European strategic autonomy and global public health

The Minister also highlighted the importance of the new HIPRA Campus for the future of biotechnology and the need for companies like HIPRA, which combine science, technology, and public commitment to strengthen Spain and Europe’s strategic health autonomy.

During the visit, Maria del Mar Nogareda, Vice President of HIPRA, stated: “The Minister’s visit highlights the effort we are making from Spain to ensure our capacity to respond to global health challenges and to prepare for potential pandemics. Our goal is clear: to drive innovation from Europe, strengthen strategic autonomy, and provide biotechnological solutions such as vaccines that protect both people and animals.”